Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
4-AMINOPYRIDINE DERIVATIVES
Document Type and Number:
WIPO Patent Application WO/1989/002740
Kind Code:
A1
Abstract:
Compounds of formula (I), wherein R1, R2, A and B are defined hereinbelow. The compounds of the present invention inhibit brain acetylcholinesterase and are useful in the treatment of Alzheimer's disease.

Inventors:
Desai
Manoj
Chandrasinhji
Application Number:
PCT/US1988/001070
Publication Date:
April 06, 1989
Filing Date:
March 30, 1988
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
PFIZER INC
Desai, Manoj Chandrasinhji
International Classes:
C07D215/42; A61K31/4706; A61K31/473; A61K31/4738; A61P25/28; C07C255/61; C07D213/84; C07D213/85; C07D219/10; C07D221/16; C07D221/22; C07D307/30; C07D309/28; C07D311/68; C07D333/36; C07D335/02; C07D335/06; C07D405/12; C07D471/04; C07D487/04; C07D491/04; C07D491/048; C07D491/052; C07D491/14; C07D491/147; C07D495/04; C07D495/14; C07D498/04; C07D513/04; (IPC1-7): A61K31/47; C07D491/048; C07D491/052; A61K31/44; C07D219/10; C07D221/22; C07D471/04; C07D491/147; C07D495/04
Foreign References:
US4180580A1979-12-25
US4680297A1987-07-14
US4680298A1987-07-14
Other References:
CHEMICAL ABSTRACTS, Volume 92, Number 1, issued 1980, (Columbus, Ohio, USA), ARNE OSBIRK et al., "Phosamides. X. Phosphorus Pentaoxide Amine Mixtures and HMPT as Reagents in the Synthesis of 4-Amino- and 4-Dimethylamino-2,3-Polymethylene-quinolines", Abstract No. 6385a; & ACTA CHEM. SCAND., SER. B (1979), B33(5), 313-18 (Eng).
Download PDF:
Claims:
CLAIMS
1. A compound of the formula wherein A is selected from the group consisting of wherein one of the CH moieties at positions a, b, c and d of formula 1_ may be replaced by a nitrogen atom or each of the CH moieties at positions a and d, a and c or b and d may be replaced by a nitrogen atom; B is selected from the group consisting of *& 10.
2. wherein each broken line represents an optional double bond; R is hydrogen or C C, alkyl; R.
3. is independently selected from the group consisting of hydrogen, C..C, alkyl, C.Cfi alkoxy, C_.Cfi alkanoyl, di(C.C6 alkylamino)C1C6 alkyl, C.Cg alkyl, halogen, hydroxy, nitro, phenyl, substituted phenyl, phenylC.C, alkyl, substituted phenylC.Cfi alkyl, diphenylC.C, alkyl wherein one or both of the phenyl groups may be replaced with a substituted phenyl group, furylC,C8 alkyl, thienylC,C8 alkyl, phenyloxy, substituted phenyloxy, NHCORD and NR R , wherein the phenyl moieties on the substituted phenyl and substituted phenylalkyl groups are substituted with one or more substituents selected from the group consisting of halogen, C. C alkyl, trifluoromethyl, C,Cg alkoxyC.C8 alkyl, hydroxy and nitro, and wherein R , R and R are independently selected from 2 C1~Cg alkyl and C. Q alkanoyl; R is independently selected from the group consisting of 1,.
4. dihydropyridylC^C alkanoyl, C Cfi alkyl1,4dihydro pyridylC.C8alkanoyl, and the possible definitions set forth above for R3, except that .R2 cannot be hydroxy, halogen, C..C alkoxy, phenyloxy or substituted phenyloxy; R 4 is independently selected from the possible definitions set forth above for R , except that R 4 cannot be halogen, nitro, NHCOR5 or NR6R7; n is 1, 2 or 3; Z1 is NH, 0, S or NR8 wherein R8 is ,C8 alkyl or C,Cβ alkanoyl; Z 2 is O or S; Z3 and Z are independently selected from (CH_ Δ)p, O, S,3S=0 and S0 , with the proviso that at least one of Z and Z 4 is (CH2) ; Z5 is CH2, O, S, S=0 or S02; Z6 is O, S, S=0 or S02; p is 1, 2 or 3; q is 1 or 2; Y is CH, CHOH, 0, C=0, S, S=0 or S02; Y2 is CH2, CH, 0, S, S=0 or S02; and Y3 is CHOH, CH2, CH or C=0, with the proviso that the group of the formula ~ may have a double bond only when both Y 2 and Y3 are CH, with the proviso that when A is a group of the formula _1 wherein 3 R is hydrogen and there is no nitrogen at position a, b, c or d or A is a group of the formula 3_ or 4_, only one of Y 1 and Y2 can be CH., and with the proviso that when A is a group of the formula 1_ wherein R 3 is hydrogen and there is no nitrogen at position a, b, c or d, only one of Z 3 and Z4 can be (CH_) ; and P pharmaceutically acceptable salts thereof.
5. 2 A compound according to claim 1, with the proviso that when A is a group of the formula _1 wherein there is no nitrogen at position a, b, c or d or A is a group of the formula ~_ or 4_, only one of Y 1 and Y2 can be CH .
6. 3A compound according to claim 2 , wherein R 1 , R 2 and R 4 are hydrogen and R 3 is hydrogen or halogen .
7. 4 A compound according to claim 3, wherein R is hydrogen or fluorine.
8. A compound according to claim 2, said compound being selected from the group consisting of compounds of the formula I wherein A is a group of the formula 1_, wherein one of the CH moieties at positions a and b of formula 1_ may be replaced by a nitrogen 2 3 atom or A is a group of the formula 3_; B, R , R , R , 4 3 4 5 3 "* R , Z , Z , Z , Y and q are as defined in claim 1; n is 1 or 2; Z is S; and p is 1 or 2; with the proviso that (a) when A is a group of the formula 1_ wherein there is no nitrogen at either position a or 3 position b, Z is O, S or CH_; R. s hydrogen 4 or C,C, alkyl; Z is (CH. , wherein p is 1 1 ^ P 2 or 2, or S; Y is CH2, C=0, 0, or S, and Y is CH_, 0 or S, with the proviso that only 1 2 one of Y and Y can be CH_; (b) when A is a group of the formula _1 wherein there is a nitrogen at either position a or position b, Y and (c) when A is a group of the formula 3_, Y is 0 2 or S; and Y is CH«; and pharmaceutically acceptable salts thereof.
9. A compound according to claim 5, wherein R , 2 4 3 R and R are hydrogen and R is hydrogen or halogen.
10. A compound according to claim 6, wherein R is hydrogen or fluorine.
11. A compound according to claim 2, wherein B is a group of the formula 1_ or §..
12. A compound according to claim 8, wherein R , R 2 and R4 are hydrogen and R3 is hydrogen or halogen.
13. A compound according to claim 9, wherein R is hydrogen or fluorine.
14. A compound according to claim 5, wherein B is a group of the formula 1_ or .§.♦.
15. A compound according to claim 11, wherein R , 2 4 3 R and R are hydrogen and R is hydrogen or halogen.
16. A compound according to claim 2, wherein R . R 2 and R4 are hydrogen and R3 is hydrogen or halogen.
17. A compound according to claim 1, wherein A is a group of the formula 1_, wherein R is as defined for 3 formula I, with the proviso that R may only be at position c of formula 1_, and R 1,R2 and B are as defined in claim 1.
18. A compound according to claim 14, wherein R is halogen.
19. A compound according to claim 15, wherein R is fluorine.
20. A compound according to claim 1, wherein A is 3a group of the formula 1_, wherein R is selected from the group' consisting of C.C8 alkyl, C.Cg alkoxy, halogen, hydroxy, nitro, NHCOR , NR R or 5 6 7 trifluoromethyl, wherein R ,R and R are as defined in claim 1; and B is a group of the formula ^^") wherein r is 2,3 or 4.
21. A compound according to claim 17, wherein R is at the c position of formula 1_.
22. A compound according to claim 17, wherein R is halogen.
23. A compound according to claim 18, wherein R is halogen.
24. A compound according to claim 19, wherein R is fluorine.
25. A compound according to claim 20, wherein R is fluorine.
26. A compound according to claim 2, said compound being selected from the group consisting of: 9amino4oxal,2,3,4tetrahydroacridine; 9aminol,2,3, tetrahydrol,4— ethanoacridine; 9amino8fluoro1,2,3,4tetrahydrol,4methano acridine; 9amino2oxal,2,3,4,tetrahydroacridine; 9amino2thial,2,3,4tetrahydroacridine; 9amino8fluoro4oxal,2,3,4tetrahydroacridine; 9amino4oxal,2,3,4,5,6,7,8octahydroacridine; 2,3dihydrothieno[3,2b]quinoline9amine; 9amino5azal,2,3,4tetrahydroacridine; 2,3dihydro8fluorothieno[3,2b]quinolin9 amine; 9aminol,2dihydroacridine4 (3H)one; .1,3dihydro8fluorothieno[3,4b]quinolin9 amine; 9amino4thial,2,3,4tetrahydroacridine; 9amino8fluoro2thial,2,3,4tetrahydroacridine; and the pharmaceutically acceptable salts of the foregoing compounds.
27. A compound according to claim 17, said compound being 8fluoro9aminol,2,3,4tetrahydro acridine or a pharmaceutically acceptable salt thereof.
28. A pharmaceutical composition for the treatment of Alzheimer's disease comprising a memory enhancing effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.
29. A method of treating Alzheimer's disease comprising administering to a patient in need of such treatment a memory enhancing effective amount of a compound according to claim 1.
30. A compound according to claim 2, wherein Y is CH2, and at least one of Z 3 and Z4 is CH2; with the proviso that when A is a group of the formula 1_ wherein R 3 i.s hydrogen and there is no ni.trogen at posi.ti.on a, b, c or d, only one of Z 3 and Z4 can be (CH _,__,.)p.
Description:
4-AMINOPYRIDINE DERIVATIVES

Background of the Invention The present invention relates to 4-aminopyridine derivatives. The compounds of the present invention inhibit brain acetylcholinesterase and are useful in the treatment of Alzheimer's disease.

Tetrahydroaminoacridine, which has anticholine¬ sterase activity, has been reported to produce improved performance in psychological tests in patients afflicted with Alzheimer's disease ( . K. Summers et al., The New England Journal of Medicine, 315, 1241-1245 (1986)) . The anticholinesterase physostigmine has also been reportedly used in the experimental treatment of Alzheimer's disease (S. D. Brinkman et al., Neurobiol. Aging, 4_, 139-145 (1983)) .

The compounds described in the following four documents are alleged to have anticholinesterase activity:

United States Patent 4,652,567 refers to benzo (C)-1,5-naphthyridines for treating Alzheimer's disease.

United States Patent 4,631,286 refers to 9-amino-l,2,3,4-tetrahydroacridine-l-ol and related compounds for treating Alzheimer's disease. United States Patent 4,550,113 refers to 9-amino-

2,3,5,6,7,8-hexahydro-lH-cyclopenta(b)quinoline mono- hydrate hydrochloride for treating neuritis, injuries of the peripheral nervous system, hereditary neuromus¬ cular diseases, and disseminated sclerosis. United States Patent 4,578,394 refers to dihydropyridines for treating Alzheimer's disease.

United States Patent 4,540,564 refers to dihydropyridines for delivering drugs to the brain.

G. K. Patnaik et al., J. Med. Chem. , S_ r 483-488 (1966) , refer to 4-substituted 2,3-polymethylene- quinolines having analgetic, local anesthetic, analeptic, and respiratory stimulant activities.

British Patent Specifications 1,186,061, 1,186,062, and 1,186,063 refer to benzonaphthyridine derivatives.

Summary of the Invention

The present invention relates to compounds of the formula

wherein A is selected from the group consisting of

d

1

wherein one of the CH moieties at positions a, b, c and d of formula 1_ may be replaced by a nitrogen atom or each of the CH moieties at positions a and d, a and c or b and d may be replaced by a nitrogen atom; B is selected from the group consisting of

10

wherein each broken line represents an optional double bond; R is hydrogen or C,-C 8 alkyl;

R is independently selected from the group consisting of hv ~droσ 'en, Cl__. -Cb c alkv-l, C __,_.- o c alkoxv~, Ci..-C0., alkanovl, di(C1,-C6, alkv-lamino) -C1-C6- alky-l, C-1-C c 6 alkoxv--C,1 -C6, alkyl, halogen (e.g., fluoro, chloro, bromc or iodo) , hydroxy, nitro, phenyl, substituted phenyl, phenyl-C.-C, alkyl, substituted phenyl-C.-C β alkyl, diphenyl-C- -C - alkyl wherein one or both of the phenyl groups may be replaced with a substituted ohenyl group, f ryl-C n -C c alkyl, thier.yl-C_.-C, alkyl, phenyloxy, substituted

5 6 7 phenyloxy, NHCOR and NR R , wherein the phenyl moieties on the substituted phenyl and substituted phenylalkyl groups are substituted with one or more substituents

(preferably, one or two substituents) selected from the

group consisting of halogen (e.g., fiuoro, chloro, bromo or iodo) , ,-C 8 alkyl, trifluoromethyl, C^-C, alkoxy-C 7 -C_ alkyl, hydroxy and nitro, and wherein R ,

6 7

R and R are independently selected from C.-Cg alkyl and C--Cg alkanoyl; R is independently selected from the group consisting of l,4-dihydropyridyl-C--Cg alkanoyl, C 1,-Co, alkyl-l,4-dihydropyridyl-C n 1-C c >-alka^noyl, and the possible definitions set forth above for R ,

2 except that R cannot be hydroxy, halogen, ^-Cg alkoxy, phenyloxy or substituted phenyloxy; R is independently selected from the possible definitions set forth above for R 3, except that R 4 cannot be

5 6 7 1 halogen, nitro, NHCOR or NR R ; n is 1, 2 or 3; Z is

NH, 0, S or NR wherein R is C,-C β alkyl or C.-C fi

2 3 4 i w alkanoyl; Z is 0 or S; Z and Z are independently selected from (CH_) , 0, S, S=0 and SO,, with the proviso that at lea Pst one of Z3 and Z4 is (CH 5 .

2)p: Z s

CH 2 , O, S, S=0 or S0_; Z is 0, S, S=0 or S0_; p is

1, 2 or 3; q is 1- or 2; Y 1 is CH 2 . CHOH, 0, C=0, S, S=0 or S0 2 ; Y 2 is CH 2 , CH, 0, S, S=0 or S0 2 ; and Y 3 is

CHOH, CH., CH or C=0, with the proviso that the group of the formula ~ [ may have a double bond only when both

Y 2 and Y3 are CH, with the proviso that when A is a

3 group of the formula 1_ wherein R is hydrogen and there is no nitrogen at position a, b, c or d or A is a group of the formula 3_ or 4_, only one of Y 1 and Y2 can be

CH ? , and with the proviso that when A is a group of the 3 formula _1 wherein R is hydrogen and there is no nitrogen at position a, b, c, or d, only one of Z and 4 Z can be (CH, 2.)p; and o-harmaceuticallv acceptable salts thereof.

The present invention also relates to a pharmaceu¬ tical composition for the treatment of Alzheimer's disease comprising a compound of the formula I and to the use of compounds of the formula I in treating

Alzheimer's disease. The present invention also relates to methods of preparing compounds of the formula I.

One embodiment of the present invention relates to compounds of the formula I wherein R 1,R2, A and B are as defined for formula I, with the proviso that when A is a group of the formula 1_ wherein there is no nitrogen at position a, b, c or d or A is a group of the formula 3_ or 4_, only one of Y " ~• and Y 2 can be CH-; and pharmaceutically acceptable salts thereof. One aspect of the foregoing embodiment relates to compounds wherein Y 3 i,s CH„, and at least one of Z3 and Z4 is

CH 7 ; with the proviso that when A is a group of the formula _! wherein R " ' is hydrogen and there is no

3 nitrogen at position a, b, c or d, only one of Z and

Z 4 can be (CH„) .

A preferred embodiment of the present invention relates to compounds of the formula I wherein A, B, Z ,

Z , Z , Z , Z , Z and Y are as defined with respect to formula I; R 1, R2 and R4 are hydrogen; and R3 is hydrogen cr halogen; with the proviso that when A is a group of the formula _!_ wherein there is no nitrogen at position a,b,c cr d, or A is a group of the formula 3_ or 4_, only one of Y " and Y" can be CH.,; and pharmaceutically acceptable salts thereof. When R" ' is halogen, the halogen is preferably fluorine.

Another preferred embodiment of the present invention relates to compounds of the formula I wherein A is a group of the formula 1_, wherein one of the CH moieties at positions a and b of formula _1 may be replaced by a nitrogen atcr., cr A is group of the formula 3_;

B, R , R 2 , R , R 4 , Z°, Z , Z 3 , Y and ς are as defined with respect to formula I; g n is 1 or 2; Z is S; and p is 1 cr 2; with the proviso that

_ _

(a) when A is a group of the formula 1_ wherein there is no nitrogen at either position a or position b , Z 3 is 0 , S or CH_ ; R 4 is hydrogen or C. -C, alkyl; Z 4 is (CH- ) , wherein p is 1

1 6 1 p 2 or 2, or S; Y is CH 2 , C=0, 0, or S, and Y is CH„, 0 or S, with the proviso that only one of Y 1 and Y2 can be CH_;

(b) when A is a group of the formula _1 wherein there- is a nitrogen at either position a or position b, Y 1 is 0, S or CH 2 and Y2 is CH.,; and

(c) when A- is a group of the formula 3_, Y is 0 or S; and Y 2 is CH ; and the pharmaceutically acceptable salts thereof. In a more preferred embodiment, R 1, R2 and R4 are hydrogen and R 3 is hydrogen or halogen. When R3 is halogen, the halogen is preferably fluorine.

Another preferred embodiment of the present invention relates to compounds of the formula I,

1 wherein B is a group of the formula 1_ or _8_ and A, P. ,

R 2 , R 3 , Z 1 , Z 2 , q, Y 1 , Y 2 and Y 3 are as defined with respect to formula I, with the proviso that when A is a group of the formula 1_ wherein there is no nitrogen at position a, b, c, cr d, or A is a group of the formula 3_ or " _4, only one of Y 1 and Y2 can be CH_; and pharmaceutically acceptable salts thereof. In a mere preferred embodiment, R 1 and R2 are hydrogen and R3 is

3 hydrogen or halogen. When R is halogen, the halogen is preferably fluorine. A particularly preferred embodiment of the present invention relates to compounds of the formula Z , wherein A is a group of the formula 1_, wherein one of the CH moieties at positions a and b of formula 1_ may be replaced bv a nitroqen atom, or A is a group of the rormula 3_; B is a group of the formula 1_ or 8_; R 1, R2,

3 1 2 3

R , q, Y , Y and Y are as defined for formula I; and n is 1 or 2; with the proviso that

(a) when A is a group of the formula _1 wherein there is no nitrogen at either position a or

1 2 . position b, Y is CH_ , C=0, 0 or S , and Y is

CH_, 0 or S, with the proviso that only one

1 2 of Y and Y can be CH 2

(b) when A is a group of the formula _1 wherein there is a nitrogen at either position a or position b, Y 1 is 0, S or CH 2 and Y2 is CH 2 and

(c) when A is a group of the formula _3, Y is 0

2 or S; and Y is CH»; and the pharmaceutically acceptable salts thereof. In

1 2 4 a more preferred embodiment, R , R and R are hydrogen and R 3 is hydrogen or halogen. When R3 is halogen, the halogen is preferably fluorine.

Another preferred embodiment of the present invention relates to compounds of the formula I,

3 . wherein A is a group of the formula 1_, wherein R is as

3 defined for formula I, with the proviso that R may

1 2 only be at position d of formula 1_, and R ,R and B are as defined for formula I, and the pharmaceutically acceptable salts thereof. In a more preferred 3 embodiment, R s halogen, more preferably, fluorine.

Another preferred embodiment of the present invention relates to compounds of the formula I,

3 . wherein A is a group of the formula 1_, wherein R is selected from the group consisting of C-.-C, alkyl,

^ f, 7 c ι" C f; alkoxy, halogen, hydroxy, nitro, NKCOR ,NR R or trifluoromethyl; B is a group cf the formula ^ ^ y > wherein r is 2,3 or 4; and R ,R ,R ,R and R' are as defined for formula I; and the pharmaceutically acceptable salts thereof. Of the foregoing compounds

3 . the more preferred compounds are those wherein R is at

3 the d position of formula 1_ or wherein R is halogen.

Particularly preferred compounds are those wherein R is halogen at the d position. When R is halogen, the halogen is preferably fluorine. Specific preferred compounds of the present invention are the following:

9-amino-4-oxa-l,2,3,4-tetrahydroacridine;

9-amino-l,2,3,4-tetrahydro-l,4-methanoacridine;

9-amino-8-fluoro-1,2,3,4-tetrahydro-l,4-methano- acridine;

9-amino-2-oxa-l,2,3,4,-tetrahydroacridine;

9-amino-2-thia-l,2,3, -tetrahydroacridine;

9-amino-8-fluoro-4-oxa-l,2,3,4-tetrahydroacridine;

9-amino-4-oxa-l,2,3,4,5,6,7,8-octahydroacridine; ,3-dihydrothieno[3,2-b]quinoline-9-amine;

9-amino-5-aza-l,2,3,4-tetrahydroacridine;

2,3-dihydro-8-fluoro-thieno[3,2-b]quinolin-9-amine;

9-amino-l,2-dihydroacri ' dine-4 (3H_)-one; l,3-dihydro-8-fluoro-thieno[3,4-b]quinolin-9-amine; 9-amino-4-thia-l,2,3,4-tetrahydroacridine;

8-fluoro-9-amino-l,2,3,4-tetrahydroacridine; and

9-amino-8-fluoro-2-thia-l,2,3,4-tetrahydroacridine.

Other compounds of the present invention are the following: 9-amino-4,5-thiaza-l,2,3,4-tetrahydroacridine;

9—amino-4-thia-l,2,3,4,5,6,7,8-octahydroacridine;

9-amino-2-thia-l,2,3,4,5,6,7,8-octahydroacridine;

9-amino-2-oxa-l,2,3,4,5,6,7,8-octahydroacridine;

9-amino-5,7-diaza-l,2,3,4-tetrahydroacridine; 9-amino-3-methyl-7-phenyl-4-oxa-l,2,3,4-tetrahydro- acridine;

9-amino-6-trifluoromethyl-1, -methano-l,2,3,4-tetra- hydroacridine;

9-amino-5,8-diaza-l,4-methano-l,2,3,4-tetrahydro- acridine;

9-amino-l-thia-l,2,3,4-tetrahydroacridine;

9-amino-3-thia-l,2,3,4-tetrahydroaσridine;

4-amino-5,6,7,8-tetrahydro-lH-imidazo [4,5-b]- quinoline;

4-amino-5,6,7,8-tetrahydro-oxazolo[4,5-b]quinoline;

4-amino-5,6,7,8-tetrahydro-thiazolo[4,5-b]quinoline;

9-amino-l,2,3,4-tetrahydroacridine-4-ol;

9-amino-6-trifluoromethyl-4-oxa-l,2,3,4-tetrahydro- acridine;

9-amino-6-trifluoromethyl-l-hydroxy-4-oxa-l,2,3,4- tetrahydroacridine; and

9-amino-l-hydroxy-4-oxa-l,2,3,4-tetrahydroacridine.

Preferred compositions of the present invention contain the foregoing preferred compounds. More preferred compositions of the present invention contain the foregoing more preferred compounds and specific preferred compounds.

Detailed Description of the Invention

Compounds of the present invention may be prepared as described below.

Scheme I

V

As shown in Scheme I, an aminonitrile of the formula II, wherein A is as defined above, is reacted with a ketone of the formula III wherein B is as defined above to prepare a ketimine of the formula IV. The reaction is conducted in an inert solvent, preferably an aromatic solvent (e.g., benzene or toluene) , in the presence of an acid, preferably a strong acid (e.g. p-toluenesulfonic acid) . The temperature should be at least about 100°C, but is otherwise not critical. Generally, the reaction is conducted at the reflux temperature of the reaction mixture, e.g., by refluxing the reaction mixture in a Dean Stark apparatus, preferably for about 6 to about 16 hours, and removing the water periodically. The reaction pressure is not critical. Generally, the reaction will be conducted at a pressure of about 0.5 to about 2 atmospheres, preferably at ambient pressure (generally, about 1 atmosphere) .

The crude ketimine IV obtained after the removal of solvent is then reacted with a base (e.g., lithium diisopropylamide) in.an inert solvent, preferably an anhydrous ether (e.g., tetrahydrofuran), at a temperature of about 0°C to about 25°C. The reaction pressure is not critical. Generally, the reaction will be conducted at a pressure of about 0.5 to about 2 atmospheres, preferably at ambient pressure (generally, about 1 atmosphere) .

The first method works especially well when an ail carbon ketone is employed in the reaction. Azeotropic removal (80°C, PTSA, 15 hours) of water from a benzene solution of norcamphor (or an ail carbcr. ketone) and anthranilonitrile afforded the corresponding ketimine which on treatment with lithium diisopropylamide (0°C, 4 hours) in tetrahydrofuran afforded the compound of Example 1 in 25% yield. The use of this procedure is

also exemplified by the preparation of the compounds of Examples 2, 3, 4, 30 and 36.

The limitation in the general applicability of the first method is the difficulty of formation of ketimines from carbonyl compounds containing a nitrogen or oxygen atom. Titanium (IV) chloride, because of its high affinity for oxygen, has been used in the preparation of ketimines. (See H. Weingarten et al., J. Org. Chem. , 32, 3246(1967)). This observation was adapted for the synthesis of 9-amino-l,2,3,4-tetrahydr- oacridine derivatives in a single step by the conden¬ sation of appropriate o-aminonitriles with diverse carbonyl components.

Thus, in a second method for preparing compounds of the present invention, a compound of the formula II wherein A is defined as above is reacted with a carbonyl-containing compound of the formula III wherein B is as defined above. The carbonyl-containing compound may be a. ketone, a lactone, or the like. The reaction is conducted in an inert solvent in the presence of a Lewis acid (e.g., titanium (IV) chloride) and, if necessary, in the presence of a base, preferably an amine base (e.g. triethylamine) . Suitable solvents include aromatic solvents (e.g., benzene cr toluene) and chlorinated solvents (e.g., methylene chloride or 1,2-dichloroethane) . The reaction temperature should be at least about 0°C and is preferably about 25 to about 120°C. The reaction pressure is not critical. Generally, the reaction will be conducted at a pressure of about 0.5 to about 2 atmospheres, preferably at ambient pressure (generally, about 1 atmosphere) .

Thus, for example, condensation of delta- valerolactone with anthranilonitrile in methylene chloride by titanium (IV) chloride at 25°C in the

presence of triethylamine (2 equivalents) afforded the compound of Example 7 (28%) . This method was adopted for the synthesis of the compounds of Examples 7-19, 26-29, 31-33, 35 and 37-46. The compounds of Examples 5 and 6 were prepared by condensing anthranilonitrile with the appropriate ketones in the presence of anhy¬ drous zinc chloride at elevated temperature (<140°C) .

Monoalkylation of the amine group in compounds of the present invention may be achieved by heating them with appropriate alkyl halides in the presence of sodium hydride in dimethylformamide. This is exemplified by the synthesis of the compounds of Examples 20-25 and 34.

The compounds of Formula I are capable of forming acid addition salts with pharmaceutically acceptable acids. The acid addition salts may be prepared by reacting the base form of the appropriate compound of formula I with one or more equivalents, preferably with an excess, of the appropriate acid in an organic solvent, for example, diethyl ether or an ethanol diethyl ether mixture. Suitable acids to form these salts include the common mineral acids, e.g. hydrohalic, sulfuric or phosphoric acid; the organic acids, e.g. ascorbic, citric, lactic, aspartic or tartaric acid or their aqueous solutions whose pH has been adjusted to 5.5 or less; and acids which are sparingly soluble in body fluids and which impart slow-release properties to their respective salts, e.g. pamoic or tannic acid or carboxymethyl cellulose. The preferred salt is the hydrochloride salt.

The compounds of formula I and the pharmaceuti¬ cally acceptable salts thereof are useful in the treatment of various memory dysfunctions associated with decreased cholinergic function such as Alzheimer's Disease. Additionally, the compounds lead to stimula-

tion of neuromuscular transmission, enhancement of excitation in excitable tissues (nerve, and smooth and striated muscle) as well as restoration of conductance in nerves, and neuromuscular synapses in the case of injury thereof. The compounds of this invention also exhibit antidepressant activities which is particularly helpful for patients suffering from Alzheimer's Disease. The compounds of this invention are, in general, less toxic and have a broader therapeutic 0 window than known compounds such as tacrine and physotigmine, making them therapeutically preferred.

In treating Alzheimer's disease, the dosage of the compounds of the present invention will vary with the form of administration and the particular compound 5 chosen. Furthermore, it will vary with the particular subject as well as the age, weight and condition of the subject under treatment as well as with the nature and extent of the symptoms. Generally, however, a dose in the range of about 1 to about 300 mg/day, taken in 0 single or divided doses, will be administered. The preferred dose is in the range of from about 1 to about 150 mg/day in single or divided doses.

Generally, treatment is initiated with small dosages substantially less than the optimum dose of the 5 compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circum¬ stances is reached.

The compounds of the present invention are used alone or in combination with pharmacologically υ acceptable carriers, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard medical practice. For example, they are administered orally in the form of capsules, tablets, suspensions or 5 solutions or they may be injected parenterally.

Capsules and tablets are the preferred mode of administration. For parenteral administration, they can be used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic.

Capsule and tablet compositions may contain the active ingredient in admixture with one or more pharmaceutical excipients suitable for the manufacture of capsules and tablets. Suitable pharmaceutical excipients are, for example, starch, milk sugar, and certain types of clay. The tablets can be uncoated or they can be coated by known techniques so as to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.

Aqueous suspensions of the compounds of formula I contain the active ingredient in ' admixture with one or more pharmaceutical excipients suitable for the manufacture of aqueous suspensions. Suitable. excipients are, for example, methylcellulose, sodium alginate, gum acacia, lecithin and so forth. Aqueous suspensions can also contain one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents. Non-aqueous suspensions can be formulated by suspending the active ingredient in a vegetable oil for example, arachis oil, olive oil, sesame oil, or coconut oil, or in mineral oil, for example liquid paraffin, and the suspension may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. These compositions can also contain a sweetening agent, flavoring agent and antioxidant.

The following examples illustrate the preparation and properties of the compounds of the present invention. All melting points are uncorrected. Thin

layer chromatography (TLC) was conducted on silica gel.

Example 1 9-Amino-l,2,3,4-tetrahydro-l,4-methanoacridine A solution of anthranilonitrile (3.6 g, 30.0 mmole) , norcamphor (3.3 g, 30.0 mmole) and para-toluenesulfonic acid (50 mg) in benzene (50 ml) was heated to reflux using a Dean Stark apparatus. After heating for 18 hours, the reaction mixture was then cooled (25°C) and the separated water (about 1.5 ml) was withdrawn. The excess benzene was then removed under vacuum (1 mm Hg, 15 minutes) . The oily residue thus obtained was dissolved in tetrahydrofuran (THF, 10 ml) and was cooled to 0°C and a solution of lithium diisopropylamide in THF (IM, 36 ml, 36 mmole) was then added. This reaction mixture was then stirred at 0°C for 3 hours. At the end of this period, the reaction mixture was quenched with 40 ml of water and was extracted with methylene chloride (200 ml) . The resulting organic phase was washed with water (2 x 50 ml) and dried (anhydrous MgSO.) . The methylene chloride was removed under vaccu to afford a residue which was loaded on a silica gel flash chromatography column. Elution with 5% methanol in methylene chloride containing 1% triethylamine afforded the title compound 1.6 g, 25%) as an oil which solidified on standing

(m.p. 185-186°C) . " H-NMR (CDC1 3 , 300 MHz, Q ): 2H, m, 1.22-1.42 ppm; IH, d, 1.64 ppm (J = 7.0 Hz); IH, d, 1.86 ppm (J = 6.0 Hz); 2H, , 1.9-2.04 ppm; 2H, bd, 3.46 ppm; 2H, bs, 4.49 ppm; IH, t, 7.38 ppm (J = 6.0 Hz); IH, t, 7.55 ppm (J = 6.0 Hz); IH, d, 7.67 ppm (J = 6.0 Hz) ; IH, d, 7.92 ppm (J = 6.0 Hz) .

Example 2 9-Amino-8-f luoro-1 , 2 , 3 , 4-tetrahydro-l , 4-methanoacridine Following the procedure of Example 1 , but subst-i- tuting 2-amino-6-f luorobenzonitrile for anthranilo-

nitrile, afforded the title compound (23%, m.p. 173°C) . ϊ-N (CDC1 3 , 300 MHz, ζ ) : 2H, m, 1.28-1.5 ppm; IH, bd, 1.68 ppm; IH, bd, 1.89 ppm; 2H, m, 1.98-2.18 ppm;

2H, bs, 3.5 ppm; 2H, bs, 5.18 ppm; IH, dd, 7.0 ppm (J. = 12.5, 8.0 Hz); IH, , 7.44 ppm (J = 12.5, 8.0 HZ); IH, d, 7.75 ppm (J = 8.0 Hz).

HRMS: Calculated - 228.1062; Found - 228.1049.

TLC: (90:10:l-methylene chloride:methanol:28% aqueous ammonia) R_ = 0.7. Example 3

9-Amino-7-chloro-l,2,3,4-tetrahydro-l,4-methanoacridine Following the procedure of Example 1, but substituting 2-amino-5-chlorobenzonitrile for anthranilonitrile, afforded the title compound (14%, m.p. 183-184°C) . " hϊ-NMR (CDC1 3 , 300 MHz,f): 2H, m,

1.3-1.56 ppm; IH, bd, 1.65 ppm; IH, bd, 1.92 ppm; 2H, m, 1.98-2.18 ppm; IH, bs, 3.5 ppm; IH, bs, 3.54 ppm;

2H, bs, 4.45 ppm; IH, dd, 7.5 ppm (J = 2, 9.0 Hz); Ih, d, 7.65 ppm (J = 2 Hz); IH, d, 7.84 ppm (J = 9.0 Hz). HRMS: Calculated - 244.0767; Found - 244.0750.

TLC: (90:10:l-methylene chloride:methanol:28% aqueous ammonia) R_ = 0.7.

Example 4

9-Amino-l,4-dihydro-l,4-methanoacridine Following the procedure of Example 1, but substituting 5-norbornen-2-one for norcamphor, afforded the title compound (26%, m.p. 123°C) . 1 H-NMR (CDC1,,

300 MHz, 0 I ) : IH, d, 2.4 ppm (J = 8.0 Hz) , IH, dt, 2.5 ppm (J = 1.7, 8.0 Hz); IH, bs, 3.88 ppm; IH, bs, 4.07 ppm; IH, bs, 4.46 ppm, 2H, s, 6.86 ppm; IH, t, 7.44 ppm

(J = 8.0 Hz); IH, t, 7.6 ppm (J = 8.0 Hz); IH, d, 7.68 ppm (J = 8.0 Hz) ; IH, d, 7.94 ppm (J = 8.0 Hz) .

HRMS: Calculated - 208.2622; Found - 208.0974.

TLC: (90:10:l-methylene chloride:methanol:28% aqueous ammonia) R f = 0.57.

Example 5 9-Amino-2-oxa-l,2,3,4-tetrahydroacridine Anthranilonitrile (25 mmole, 2.95 g) , zinc chloride (3.1 g, 25 mmole) and tetrahydro-4H-pyran-4- one were dissolved in toluene (40 ml) and heated to reflux for 2.5 days. At the end of this period, the reaction mixture was cooled (25°C) , was quenched with aqueous sodium hydroxide (70 ml) and was extracted with methylene chloride (4 x 60 ml) . The combined organic

10 phases were washed with water (2 x 100 ml) and dried (anhydrous MgSO.) . The organic solvents were removed under vacuum to yield a yellow residue which was loaded on a silica gel flash chromatography column. Elution with 5% methanol in methylene chloride afforded the i-5 title compound as yellow crystals (155 mg, 31%, m.p.

195-196°C) . 1 H-NMR (CDC1 3 , 300 Hz, f ): 2H, t, 3.08 ppm (J = 6.0 Hz) ; 2H, t, 4.06 ppm (J = 6.0 Hz); 2H, bs, 4.47 ppm; 2H, s, 4.74 ppm; IH, t, 7.34 (J = 8.0 Hz); IH, t, 7.54 (J = 8.0 Hz); IH, d, 7.64 (J = 8.0 Hz); IH, zo d, 7.84 (J - 8.0 Hz). TLC: (TLC plate pretreated with 2% triethylamine in hexane; eluant: 5% methanol in methylene chloride) R ^ = 0.25.

Example 6 9-Amino-2-thia-l,2,3,4-tetrahydroacridine

25 Anthranilonitrile (2.6 g, 21.5 mmole) , tetrahydro- thiopyran-4-one (5.0 g, 43 mmole) and zinc chloride (2.54 g, 21.5 mmole) were combined and heated to 120°C for 20 minutes. The reaction mixture was cooled and the solid residue was filtered using ethyl ether (100

30 ml) . The resulting orange solid (5.2 g) was placed in a beaker containing a saturated solution of EDTA (ethylene diamine tetracetic acid) in water (125 ml) and the pH was adjusted to 13 with the help of 12% NaOH. The aqueous phase was then extracted with

35 methylene chloride (4 x 50 ml) which was washed with

water (2 x 70 ml) and dried (MgSO .} . Removal of methylene chloride under vacuum afforded a yellow paste (2.0 g) which was triturated with ether and filtered to afford a light yellow solid (1.36 g, 29%, m.p. 205°C dec). 1 H-NMR (CDC1 3 , 300 MHz, f ) : 2H, 5, 3.0 ppm (J = 6.0 Hz) ; 2H, t, 3.35 ppm (J = 6.0 Hz) ; 2H, s, 3.72 ppm; 2H, bs, 4.69 ppm; IH, t, 7.4 (J = 8.0 Hz); IH, t, 7.6 (J = 8.0 Hz); IH, d, 7.69 (J = 8.0 Hz); IH, d, 7.88 (J = 8.0 Hz) . HRMS: Calculated - 216.0719; Found - 216.0688. TLC: (TLC plate pretreated with 2% triethylamine in hexane; eluant:5% methanol in methylenechloride) R f = 0.23.

Example 7 9-Amino-4-oxa-l,2,3,4-tetrahydroacridine To a stirred solution of delta-valerolactone

1.0 g, 10.0 mmole) in methylene chloride (10 ml) at -20°C, a IM solution of titanium(IV) chloride in methylene chloride (20 ml) was added. The reaction mixture became dark yellow in color and to it a mixture of triethylamine (2.0 g, 20 mmole) and anthranilonitrile (1.2 g, 10.0 mmlole) in methylene chloride (30 ml) were added. The reaction mixture immediately became dark in color and was allowed to warm to room temperature (about 25°C) and stirred further for 15 hours. At the end of this period, the reaction mixture was treated with 25% aqueous NaOH (4G ml) and methylene chloride (100 ml) and was filtered through a 2 inch diatomaceous earth pad (Celite (trade¬ mark) ) which was washed with methylene chloride (50 ml) and water (100 ml) . The organic layer was separated, washed once with water (30 ml) and dried (anhydrous MgSO.) . The methylene chloride was removed under vacuum to afford an oil which was triturated with ether to give the title compound as a white solid (565 mg, 28%). ' " H-NMR (CDC1 3 , 300 MHz, J ) : 2H m, 2.02-2.18

ppm; 2H, t, 2.63 ppm (J = .6.0 Hz) ; 2H, t, 4.36 ppm (J = 6.0 Hz); 2H, s, 4.64 ppm; IH, t,.7.25 (J = 8.0 Hz); IH, t, 7.5 (J = 8.0 Hz); IH, d, 7.72 (J = 8.0 Hz) . HRMS: Calculated - 200.2396; Found - 200.0945. Analysis: Calculated for C., H., 2 2 0: 71.98%C; 6.04%H;

13.99%N. Found: 70.91%C; 6.01%H; 14.19%N. TLC: (90:10: 1-methylene chloride:methanol:28% aqueous ammonia) R = 0.45.

Example 8 9-Amino-8-fluoro-4-oxa-l,2,3,4-tetrahydroacridine Following the procedure of Example 7, but substituting 2-amino-6-fluorobenzonitrile for anthranilonitrile afforded the title compound (8%, m.p. 195-196°C) . 1 H-NMR (CDC1 3 , 300 MHz, f ) : 2H, m, 2.06-2.2 ppm; 2H, t, 2.6 ppm (J = 6.0 Hz); 2H, t, 4.37 ppm (J = 6.0 Hz) ; 2H, bs, 5.4 ppm; IH, dd, 6.88 (J = 14.0,7.5 Hz); IH, m, 7.3-7.44; IH, d, 7.56 (J = 8.6 Hz) . HRMS: Calculated - 218.0801; Found - 218.0284 TLC: (90:10:l-methylene chloride:methanol:28% aqueous ammonia) R Λ = 0.7.

Example 9 9-Amino-7-chloro-4-oxa-l,2,3,4-tetrahydroacridine Following the procedure of Example 7, but substituting 2-amino-5-chlorobenzonitrile for anthranilonitrile afforded the title compound (2%, m.p. 278-279°C) . 1 H-NMR(CDCi 3 , 300 MHz, Q ) : 2H, m, 2.06-2.2 ppm; 2H, 5, 2.66 ppm (J = 6.0 Hz); 2H, t, 4.37 ppm (J = 6.0 Hz); 2H, bs, 4.61 ppm; IH, dd, 7.45 (J = 9.0, 1.0 Hz); IH, bs, 7.58 ppm (J = 1 Hz); IH, d, 7.66 (J = 9.0 Hz) . HRMS: Calculated - 234.056? Found -

234.0566. TLC: (90:10:1-methylene chloridemethanol:28% aqueous ammonia) R, = 0.6.

Example 10 9-Amino-4-oxa-l,2,3,4,5-,6,7,8-octahydroacridine Following the method of Example 7, but

substituting 2-amino-l-cyano-l-cyclohexene for anthranilonitrile. affcrded the title compound (8%, m.p. 145°) . ^Η-KMR (CDC1-, 300 MHz, } ) : 4H, m, 1.65-1.9 ppm; 2H t q, 2.07 ppm (J = 6.0 HZJ ; 2H, t, 2.4 ppm (J = 6.0 Hz) ; 2H, t, 2.5 ppm (J = €.0 Hz) ; 2H, p, 2.76 ppm (J = 6.0 Hz) ? 4H, bt, 4.26 ppm. HRMS: Calculated - 204.2712; Found - 204.1227. TLC: (90:10: 1-methylene chloride: ethane1: 23% aqueous ammonia) R.^ = 0.46. Example 11

9-Amino-2,3,7,8-tetrahydro-lH-cvclopenta[el 5H-pyrano- [2'3'-b] pyridine

Following the method of Example 7, bu ~ substituting 2-amino-l-cyano-l-cyclopentene for anthranilonitrile, afforded the title compound {22%, m.p. 164°C) . " H-NKR (CDC1- f 300 MHz, £ ) : 4H, m, 2.0-2.2 ppm; 2H, t, 2.48 ppm (J = 6.0 Hz) ; 2H, t, 2.68 ppm (J = 6.0 Hz) ; 2H, t, 2.87 ppm (J = 6.0 Hz) ; 2H, bs, 4.06 ppm (J = 6.0 Hz) ; 2H, t, 4.24 ppm. HRMS: Calculated - 190.1107; Found - 190.1107.

TLC: (90:10 :1-methyieπe chloride methanol:2S% aqueous ammonia) R- = 0.86.

Example 12 2,3-Dihydrothieno [3 ,2-B]quinolin-9-amine To a stirred solution of tetrahyάrothiophen-3-one

(1.1 g, 11 mmole) in methylene chloride (10 mi) at -78°C, a IM solution of tirar.ium{IV) chloride in metnviene cnicr de (n ι_x) was ac.c_.eG, A mixture _ triethylamine (2.2 g, 22 m cie) and anthranilonitrile (1.2 gms, ICO mole) in methylene chloride (30 ml; w s then added t- ~ the reaction mixture over a period of 5 minutes. The reaction mix e was then slowly warmed to room temperature and stirred for 2 hours. Tεtrahydroph ophεn-3-cne (1 ml) and titanium(I " ) chloride (1.0 ml; was then ad e

mixture and the mixture was stirred at 25°C for 16 hours. Thereafter, the reaction mixture was quenched with 12% aqueous NaOH (100 ml) and the reaction mixture was then stirred vigorously with additional methylene 5 chloride (300 ml) . The reaction mixture was then filtered through diatomaceous earth (Celite

(trademark)) and the organic phase was separated. The organic solvents were removed under vacuum to afford a residue which was loaded on a flash chromatography 1° column. Elution with 5% methanol in methylene chloride containing 1% triethylamine, afforded the title compound (1.3 gms, 64%) which was crystallized from chloroform (560 mg, 32%, m.p. 208-210°C) . H-NMR

(CDC1 " 3,, 300 MHz, f ) : 4H, m, 3.4-3.56 ppm; 2H, bs, 4.51

15 ppm; IH, dt, 7.37 ppm (J = 7.0, 1.0 Hz) ; IH, dt, 7.52 ppm (J = 7.0, 1.10 ppm) ; IH, dd, 7.61 ppm (J = 7.0, 1.0 ppm) ; IH, dd, 7.61 ppm (J = 7.0, 1.0 ppm) , IH, dd, 7.86 ppm (J = 7.0, 1.0 ppm) . HRMS: Calculated - 202.0575;

Found - 202.0545.

20 Analysis: Calculated for C χ H. Q N S: 65.32%C; 4.98%H; 13.85%N; 15.85%S. Found: 65.06%C; 5.00%H; 13.79%N; 15.63%S.

Example 13 9-Amino-l ,2,3,4,5,6,7, 8-octahydro-l ,4-methanoacridine

-- To a stirred solution of norcamphor (0.9 g, 8.2 mmole) in methylene chloride (8.0 ml) at -20°C, a mixture of triethylamine (1.7 g, 16.4 mmole) and 2-amino-l-cyano-l-cyclohexene (1.0 g, 8.2 mmole) in methylene chloride (24 ml) was added and the resulting

30 mixture was stirred at 25°C for 15 hours. The reaction mixture was then quenched with 12% aqueous NaCE f60 ml) and was stirred vigorously with methylene chloride (60 ml) . The reaction mixture was then filtered through a 2" pad of diatomaceous earth (Celite (trademark)) . The

35 organic phase' was separated, washed with water (2 x 50

ml) and then dried (anhydrous Mσ/SO •4.) . Methvlene chloride was then removed under reduced pressure to afford an oil which was triturated with pentane to give the title compound as a off-white solid (225 mg, 13%, m.p. 131-133°C) . ' " H-NMR (CDC1 3 , 300 MHz, f ) : 2H, m, 1.15-2.38 ppm; IH, d, 1.5 ppm; 7H, m, 165-2.0 ppm; 2H, bs, 2.4 ppm; 2H, bd, 2.8 ppm; 2H, bd 3.3 ppm; 2H, s, 3.95 ppm. HRMS: Calculated - 214.3096; Found - 214.1466. TLC: (90:10:1-methylene chloride:

10 methanol:28% aqueous ammonia) R_ = 0.25

Example 14 9-Amino-6-aza-l,2,3,4-tetrahydroacridine Titanium(IV) chloride (1.5 ml) was added to a stirred solution of 3-amino-4-cyano-pyridine (500 mg, -^ 4.2 mmole) and cyclohexanone (0.5 ml) in 1,2-dichloro- ethane (15 ml) . The reaction mixture was then main¬ tained at 90°C for 12 hours. At the end of this - period, cyclohexanone (2.0 ml) and 1,2-dichloroethane (5.0 ml) were added to the reaction mixture and the 20 heating was continued for another 12 hours. Additional cyclohexanone (2.0 ml) and titanium tetrachloride (1.2 ml) were then added and ' the reaction mixture was maintained at 90°C for 6 hours. The reaction mixture was then cooled and was quenched with 5% aqueous NaOH 25 (250 ml) and was stirred vigorously with methylene chloride (200 ml, 25 minutes) . The reaction mixture was then treated as in Example 8 to afford the title compound (170 mg, 95% pure, 20%) after flash chromatography on silica gel (eluant: 5:5:1; methylene

30 chloride: methanol:ammonium hydroxide. This material was further purified by chromatography to afford the title compound (75 mg, m.p. 180-181°C) . H-NMR (CDC1 3 + CD OD, 300 MHz, if ) : 4H, m, 1.9 ppm; 2H, bt, 2.54 ppm; 2H, s, 2.9 ppm; 2H, bt, 2.94 ppm; IH, d, 7.52 ppm

35 (J = 6.0 HZ) ; IH, d, 8.24 ppm (J = 6.0 Hz) ; IH, s, 9.06 ppm. HRMS: Calculated - 199.1109; Found - 199.1079.

Example 15 9-Amino-5-aza-l,2,3,4-tetrahydroacridine Following the method of Example 14, but substituting 2-amino-3-cyano-pyridine for 3-amino-4- cyano-pyridine, afforded the title compound (38%, m.p. 225-228°C dec). 1 H-NMR (CDC1 3 +CD 3 0D, 300 MHz, (f ) : 4H, bs, 1.86 ppm; 2H, bt, 2.5 ppm; 2H, bt, 2.97 ppm; 2H, vbs, 3.0-3.3 ppm; IH, dd, 7.2 ppm (J = 8.0, 4.0 Hz); IH, dd, 8.18 ppm (J = 8.0, 1-2 Hz); IH, dd, 8.77 ppm (J = 4.0, 1-2 Hz). HRMS: Calculated - 199.1109; Found - 199.1102.

Example 16 9-Amino-4 ,5-oxaza-l,2,3,4-tetrahydroacridine To a stirred solution of 2-amino-3-cyano-pyridine (360 mg, 3.0 mmole) and delta-valerolactone (360 mg,

3.6 mmole) in 1,2-dichloroethane (7.0 ml) , titaniu (IV) chloride (0.9 ml) was added and then the reaction mixture was maintained at 90°C for 18 hours. The reaction mixture was then quenched with 15% aqueous NaOH (200 ml) and was stirred vigorously with methylene chloride (200 ml, 25 minutes). The reaction mixture was then worked up as in example 15 to afford the title compound (8%, m.p. 269-270°C dec). 1 H-NMR (CDC1 3 +CD 3 0D, 300 MHz,i ) : 2H, q, 2.04 ppm (J = 6.5 Hz); 2H, t, 2.5 ' / ppm (J = 6.5 ppm); 2H, bs, 3.76 ppm; 2H, t, 4.28 ppm (J = 6.5 Hz); IH, dd, 7.11 ppm (J = 8.0, 4.0 Hz); IH, dd, 8.16 ppm (J = 8.0, 1-2 Hz); IH, dd, 8.64 ppm (J = 4.0, 1-2 Hz) .HRMS: Calculated - 201.0902; Found - 201.0864.

Example 17 9-Amino-4,6-oxaza-l,2,3,4-tetrahydroacridine

Following the method of Example 16, but substi¬ tuting 3-amino-4-cyano-pyridine for 2-amino-3-cyano- pyridine, afforded the title compound (16%, m.p. 237-238°C) . 1 H-NMR (CDC1 3 +CD 3 0D, 300 MHz,«T): 2H, q, 2.06 ppm (J = 6.5 Hz); 2H, t, 2.59 ppm (J = 6.5 ppm);

2H, s, 3.56 ppm; 2H, t, 4.3 ppm (J = 6.5 Hz); IH, d, 7.56 ppm (J = 6.0 Hz); IH, d, 8.18 ppm (J = 6.0 Hz); IH, s, 8.84 ppm. HRMS: Calculated - 201.0902; Found - 201.0892.

Example 18 9-Amino-5-aza-l,2,3,4-tetrahydro-l,4-methanoacridine

Following the method of Example 16, but substituting norcamphor for delta-valerolactone afforded the title compound (29%, m.p. 243-244°C) . 1 H-NMR (CDC1 3 +CD 3 0D, 300 MHz, f ): 2H, m, 1.2-1.4 ppm; IH, bd, 1.6 ppm (J = 6.0 Hz); IH, bd, 1.81 ppm (J = 6.0 Hz); 2H, m, 1.88-2.04 ppm; 2H, bs, 3.26 ppm; IH, bs, 3.43 ppm; IH, bs, 3.48 ppm; IH, dd, 7.23 ppm (J = 8.03, 3.0 Hz); IH, d, 8.17 ppm (J = 8.0 Hz); IH, d, 8.76 ppm (J = 3.0 Hz). HRMS: Calculated - 211.1109. Found - 211.1120.

Example 19 9-Amino-6-aza-l,2,3,4-tetrahydro-l,4-methanoacridine Following the method of Example 16, but substituting norcamphor for delta-valerolactone and

3-amino-4-cyano-pyridine for 2-amino-3-cyano-pyridine, afforded the title compound (16%, m.p. 236-237°C) . " " " H-NMR (CDC1 3 +CD 3 0D, 300 MHz, J ) : 2H, bq, 1.3 ppm; IH, bd, 1.62 ppm; IH, bd, 1.83 ppm; 2H, m, 1.9-2.1 ppm; 2E, s, 3.4 ppm; 1Ξ, bs, 3.42 ppm; IH, bs, 3.5 ppm; IH, d,

7.6 ppm (J = 6.0 Hz); IH, d, 8.31 ppm (J = 6.0 Hz); IH, s, 9.07 ppm. HRMS: Calculated - 211.1109; Found - 211.1103.

Example 20 9-Cyclohexylmethylamino-8-fluoro-4-oxa-l,2,3,4-tetra- hvdroacridine

A mixture of sodium hydride (60% oil, 110 mg, 2.75 mmole) , the title compound of Example 6 (600 mg, 2.75 mmole, cyclohexylmethyl bromide (487 mg, 2.75 mmole) and dimethylfor amide (3.0 ml) were heated with

stirring at 25°C for 12 hours and then at 65°C for 12 hours. At the end of this period, the reaction mixture was quenched by pouring it into water (45 ml) and the resulting mixture was then extracted with ethyl acetate 5 (3 x 35 ml) . The combined organic layer was washed with water (2 x 40 ml) and dried (anhydrous MgSO.) . The ethyl acetate was removed under vacuum to afford a residue which was loaded on a flash chromatography column packed with silica gel. Elution with ethyl

10 acetate afforded an oil which solidified on standing. Trituration of this solid with pentane afforded the title compound (110 mg, 13%) as a tan crystalline solid (m.p. 100°C) . 1 H-NMR (CDClg, 300 MHz <J ) : 2H, , 0.9-1.04 ppm; 3H, m, 1.04-1.32 ppm; 6H, m, 1.6-1.86

15- ppm; 2H, m, 1.88-2.04 ppm; 2H, t, 2.79 ppm (J = 6.0 Hz); 2H, bs, 3.17 ppm; 2H, t, 4.38 ppm (J = 6.0 Hz); IH, bd, 5.79 ppm (J = 20 Hz); IH, dd, 6.84 ppm (J = 140, 7.5 Hz); IH, dd, 7.32 ppm; IH, d, 7.48 ppm (J = 8.2 Hz). HRMS: Calculated - 314.1759; Found -

20 314.1787. TLC: (ethylacetate) R f = 0.35.

Example 21 9-Cyclohexylethylamino-8-fluoro-4-oxa-l,2,3,4-tetrahydro- acridine

Following the method of Example 20, but substi-

2.5 tuting cyclohexylethyl bromide for cyclohexylmethyl bromide, afforded the title compound (34%) . " " " H-NMR (CDC1 3 , 300 MHz, ύ ): 2H, m, 0.8-1.02 ppm; 4H, m, 1.02-1.4 ppm; 2H, m, 1.44-1.56 ppm; 5H, bd, 1.56-1.8 ppm; 2H, q, 1.92-2.04 ppm (J = 6.0 Hz) ; 2H, t, 2.8 ppm

30 (J = 6 Hz); 2H, bt, 3.33 ppm; 2H, t, 4.36 ppm (J = β

Hz); IH, bd, 5.6 ppm (J = 20 Hz); IH, dd, 6.38 ppm (J = 14.0, 7.5 Hz); IH, dd, 7.24-7.38 ppm; IH, d, 7.48 ppm (J = 8.2 Hz). HRMS: Calculated - 328.1951; Found - 328.1909. Analysis: Calculated for C 2Q H 25 N 2 0F:73.14%C;

35 7.67%H; 8.53%N. Found: 73.23%C; 7.93%H; 8.52%N. TLC: (ethyl acetate) R = 0.45.

Examp—le 22

9-Benzvlamino-8-fluoro-4-oxa-l,2,3, 4-tetrahvdroacridine

Following the method of Example 20 , but substituting benzyl bromide for cyclohexylmethyl

5 bromide, afforded the title compound (38%, m.p.

134-135°C) . 1 H-NMR (CDClg, 300 MHz, f) : 2H, q, 1.98 ppm (J = 6 Hz) ; 2H, t, 2.87 ppm (J = 6.0 Hz) ; 2H, t, 4.37 ppm (J = 6 Hz) ; 2H, bs, 4.48 ppm; IH, bd, 5.87 ppm (J = 20 Hz); IH, dd, 6.84 ppm (J = 14, 7.5 Hz) ; 6H, , 0 7.22-7.4 ppm; IH, d, 7.52 ppm (J = 8.2 Hz) . HRMS: Calculated - 308.1325; Found - 308.1316. Analysis: Calculated for C lg H 17 2 0F:74.01%C; 5.56%H; 9.08%N. Found: 73.68%C; 5.61%H; 9.01%N. TLC: (ethyl acetate) R f = 0.37. 5 Example 23

9-Phenethylamino-8-fluoro-4-oxa-l ,2,3,4-tetrahydro- acridine

Following the method of Example 20 but substituting (2-bromoethyl)benzene for cyclohexylmethyl 0 bromide afforded the title compound (20%, m.p.

125-126°C) . 1 H-NMR (CDC1.,, 300 MHz, <f ) : 2H, q, 1.92 ppm (J = 6 Hz) ; 2H, t, 2.69 ppm (J = 6.0 Hz) ; 2H, m, 2.9-3.0 ppm; 2H, bt, 3.38 ppm; 2H, m, 4.3-4.42 ppm; IH, bd, 5.96 ppm (J « 20 Hz) ; IH, dd, 6.78 ppm (J = 14, 7.5

25 Hz) ; IH, d, 7.14 ppm (J = 8.6 Hz) ; 6H, m, 7.22-7.4 ppm. HRMS: Calculated - 322.3809; Found- 322.1486. . TLC: (ethyl acetate) R f = 0.53.

Example 24 9-Phenpropylamino-8-fluoro-4-oxa-l ,2,3,4-tetrahydro-

30 acridine

Following the method of Example 20, but substituting l-bromo-3-phenylpropane for cyclohexylmethyl bromide, afforded the title compound (53% oil), 1 H-NMR (CDC1 3 , 300 MHz, <T) : 4H, m, 1.82-2.02 ppm; 4H, m, 2.62-2.78

'35 ppm; 2K, bs, 2.34 ppm; 2H, t, 4.35 ppm (J = 6.0 Hz) ;

IH, bd, 5.7 ppm (J = 20 Hz) ; IH, dd, 6.86 ppm (J = 14, 7.5 Hz) ; 6H, m, 7.04-7.4 ppm; IH, d, 7.51 ppm (J = 8.2 Hz) . HRMS: Calculated - 336.1638; Found - 336.1649. TLC: (ethyl acetate) R f = 0.38. 5 Example 25

9- (3 ,3-Diphenylpropylamino) -8-fluoro-4-oxa-l ,2,3,4- tetrahydroacridine

Following the method of Example 20, but substitu¬ ting l-bromo-3 ,3-diphenylpropane for cyclohexylmethyl ° bromide, afforded the title compound (32%, m.p.

134-135°C) . 1 H-NMR (CDC1 3 , 300 MHz, if) : 2H, q, 1.9 ppm (J = 6 Hz) ; 2H, q, 2.36 ppm (J = 6.0 Hz) ; 2H, t, 2.51 ppm (J = 6 Hz) ; 2H, bs, 3.32 ppm; IH, t, 4.0 (J = 6 Hz) ; 2H, t, 4.31 ppm (J = 6 Hz) ; IH, bs, 5.72 ppm (J 5 = 20 Hz) ; IH, dd, 6.9 ppm (J = 14.0, 7.5 Hz) ; 10H, , 7.1-7.3 ppm; IH, dd, 7.3-7.4 ppm; IH, d, 7.52 ppm (J = 8.2 Hz) . HRMS: Calculated - 412.1951; Found - 412.2004.

Analysis: Calculated for C 2 _H 2 _N 2 0F:78.62%c; 6.11%H; 0 6.79%N. Found: 78.08%C; 5.95%H; 6.70%N. TLC: (ethyl acetate) R f = 0.48.

Example 26 9-Amino-4-thia-l ,2,3, 4-tetrahydroacridine Following the method of Example 7, but substitut- 5 ing delta-thiovalerolactone for delta-valerolactone

1 afforded the title compound (4%,m.p.190°C) . H-NMR

(CDC1 3 , 300 MHz,o) : 2H, m, 2.22-2.3 ppm; 2H, t, 2.73 ppm (J = 6.5 Hz) ; 2H, m, 3.1-3.2 ppm; 2H, bs, 4.66 ppm;

IH, t, 7.32 ppm (J=8 Hz) ; IH, t, 7.54 ppm (J = 8 Hz) ; 1 0 H, d, 7.62 ppm (J=8 Hz) ; IH, d, 7.8 ppm (J = 8 Hz) .

HRMS: Calculated - 216.0723; Found - 216.0735.

TLC: (90 :10:l-methylene chloride : methanol : 28% aqueous ammonia) R f -0.61.

Example 27 5 9-Amino-3-methyl-4-oxa-l ,2,3, 4-tetrahydroacridine

Following the method of Example 7, but

substituting 6-methyl-tetrahydropyran-2-one for delta-valerolactone, afforded the title compound (23%,m.p.202-203°C) . " ' " H-NMR (CDClg, 300 MHz,f): 3H, d, 1.45 ppm (J = 6.5 Hz); IH, m, 1.7-1.84 ppm; IH, m, 2.04-2.18 ppm; 2H, m, 2.58-2.64 ppm; IH, , 4.22-4.36 ppm; 2H, bs, 4.69ppm; IH, t, 7.22 ppm (J = 7.5 Hz); IH, t, 7.47 ppm (J = 7.5 Hz); IH, d, 7.58 ppm (J = 7.5 Hz); IH, d, 7.71 ppm (J = 7.5 Hz).. HRMS: Calculated - 214.269; Found - 214.1138. Example 28

9-Amino-3-methyl-8-f luoro-4-oxa-l ,2,3, 4-tetrahydroacri- dine

Following the method of Example 7 , but substituting 6-methyl-tetrahydropyran-2-one for delta-valerolactone and 2-amino-6-fluorobenzonitrile for anthranilonitrile afforded the title compound (13%, m.p. 217-218°C) . 1 H-NMR (CDC1 3 , 300 MHz,/) : 3H, d, 1.45 ppm (J = 6.5 Hz) ; IH, m, 2.65-2.84 ppm; IH, , 2.06-2.19 ppm; 2H, m, 2.5-2.6 " ppm: IH, m, 4.21-4.38 ppm; 2H, bs , 5.25 ppm; IH, dd, 6.8 ppm (J = 7.5, 14

Hz); IH, dd, 7.32 ppm (J = 8 Hz, 14.0 Hz); IH, d, 7.5 ppm. (J = 8 Hz). HRMS: Calculated - 232.1026; Found - 232.1012 TLC: (90:10:1-methylene chloride : methanol : 28% aαrueous a mcnia) R ^ -0.76. Example 29

9-Amino-8-fluoro-2-thia-l,2,3,4-tetrahydroacridine Following the method of Example 7, but substituting tetrahydrothiopyran-4-one for delta-valerolactone and 2-amino-6-fluorobenzonitrile for anthranilonitrile, afforded the title compound ι

(19%, m.p. I75-176°C) . "H-NMR (CDC1.,, 300 !-:HZ, ) : 2H, t, 2.96 ppm (J = 6.2 Hz); 2H, t, 3.3 ppm (J = 6.2 Hz) ;

2H, s, 3.6 ppm; 2H, bs, 5.34 ppm; IH, dd, 6.94 ppm (J =

6.2, 14 Hz); IH, dd, 7.42 ppm (J = 8.6, 14 Hz); IH, d, 7.61 ppm (J = 8.6 Hz). HRMS: Calculated - 234.067;

Found - 234.0605; TLC: (ethyl acetate) R £ - 0.23.

Example 30 9-Amino-l,2,3,4-tetrahydro-l,4-ethanoacridine Following the method of Example 1, but substituting bicyclo[2.2.2]octan-2-one for norcamphor afforded the title compound (20%, m.p. 197-199°C) .

' " H-NMR (CDC1 3 , 300 MHz,f): 2H, m, 1.4-1.58 ppm; 2H, m, 1.58-1.74 ppm; 4H, m, 1.8-2.0 ppm; 2H, bs, 3.2 ppm; 2H, bs, 4.65 ppm; IH, t, 7.4 ppm (J = 8.5Hz); IH, t, 7.58 ppm (J = 8.5 Hz) ; IH, d, 7.71 ppm (J = 8.5 Hz) ; IH, 7.97 ppm (J = 8.5 Hz). TLC: (90:10:1-methylene chloride:methanol:28% aqueous ammonia) R--0.35.

Example 31 2,3-Dihydrofuro[2,3-b1quinolin-4-amine Following the method of Example 7, but substituting gamma-butyrolactone for delta- valerolactone afforded the title compound (m.p. 300°C dec). 1 H-NMR (CDC1.,, 300 MHz,ιf) : 2H, t, 3.17 ppm (J = 8 Hz); 2H, bs, 4.6 ppm; 2H, t, 4.69..ppm (J = 8 Hz) ; IH, t, 7.28 ppm (J = 8 Hz); IH, t, 7.53 ppm (J = 8 Hz) ; IH, d, 7.62 ppm (J = 8 Hz); IH, d, 7.77 ppm (J = 8 Hz). LRMS: Found - 186.

Example 32 6H- [l]Benzopyrano[4,3-b]quinolin-7-amine Following the method of Example 7, but substituting 4-chromanone for delta-valerolactone afforded the title compound (3%, m.p. 275°C dec). 1 H-NMR (DMSO, 300 MHz,(f): 2H, s, 5.3 ppm; IH, d, 6.97 ppm (J = 8.2 Hz) ; IH, t, 7.08 ppm (J = 7.0 Hz); 2H, , 7.15-7.4 ppm; IH, t, 7.57 ppm (J = 7.0 Hz); IH, d, 7.78 ppm (j = 7.0 Hz) ; IH, d, 8.16 ppm (J = 8.0Hz); IH, dd, 8.24 ppm (J = 7.0, 2.0 Hz). HRMS: Calculated - 248.287; Found - 248.0908; TLC: (90:10:1-methylene chloride:methanol:28% aqueous ammonia) R^-0.65.

Examp-le 33

6H-[1]Benzothiopyrano[4,3-b quinolin-7-amine Following the method of Example 7, but substituting thiochroman-4-one for delta-valerolactone afforded the title compound (13%, m.p. 211-212°C) .

H-NMR (CDC1 3 , 300 MHz,^): 2H, s, 3.94 ppm; 2H, bs 4.7 ppm; 4H, , 7.23-7.44 ppm; IH, t, 7.61 ppm (J = 7 Hz); IH, d, 7.7 ppm (J = 7 Hz); IH, d, 8.02 ppm (J = 7.0 Hz); IH, 8.5 ppm (J = 7.0,2.0 Hz). HRMS: Calculated - 264.0721; Found - 264.0715; TLC: (90:10:l-meth lene chloride:methanol:28% aqueous ammonia) R. p -0.77.

Example 34 9-Methylamino-8-fluoro-4-oxa-l,2,3,4-tetrahydroacridine Following the method Example 20, but substituting iodomethane for cyclohexylmethyl bromide afforded the title compound (for HC1 salt:m.p. 240°C) . H-NMR (DMSO, 300 MHz,f): 2H, m, 2.0 ppm; 2H, t, 2.95 ppm (J = 6.5Hz); 3H, bd, 3.3 ppm; 2H, t, 4.53 ppm (J = 6.5 Hz); IH, dd, 7.34 ppm (J = 8, 14 Hz); IH, dd, 7.44 ppm- (J = 8.0Hz); IH, m, 7.7-7.8 ppm; IH, bm, 7.94-8.06 ppm.

Example 35 2,3-Dihydro-8-fluorothieno[3,2-b]quinolin-9-amine (Compound A) and

1,3-Dlhydro-8-fluoro-thieno[3,4-b_. quinolin-9-amine (Compound B)

Following the method of Example 12 but substituting 2-amino-6-fluorobenzonitrile for anthranilonitrile afforded a 1:1 mixture of the two title compounds. Compound A (m.p. 137°C) : H-NMR (CDC1 3 , 300 MHz,f) : 4H, m, 3.48 ppm; 2H, bs, 5.09 ppm; IH, d, 6.98 ppm (J = 7.3, 14.5 Hz); IH, dd, 7.38 ppm (J = 7.3, 10.5 Hz) ; IH, d, 7.64 ppm (J = 10.5Hz); TLC:

(ethyl acetate) R--0.38.

Compound B (m.p. 198°C dec.) 1H-NMR (CDClg, 300 MHz,0r): 2H, s, 4.09 ppm; 2H, s, 4.38 ppm; 2H, bs, 5.3 ppm; IH,

dd, 7.0 ppm (J = 7.3, 14.5 Hz); IH, dd, 7.47 ppm (J = 7.3, 10.5 Hz); IH, d, 7.68 ppm (J = 10.5Hz); TLC: (ethyl acetate) R f -0.49.

Example 36 9-Amino-l,2-dihyroacridine-4 (32)-one Following the method of Example 1, but substituting 1,2-cyclohexanedione for norcamphor, afforded the title compound (11%, m.p. 240°C dec) . " " " H-NMR (CDC1 3 , 300 MHz,^) : 2H, quin, 2.31 ppm; 4H, mt,

10 2.8-2.95 ppm; 2H, bs, 4.95 ppm; IH, t, 7.29 ppm (J =

8.5 Hz); IH, t, 7.64 ppm (J = 8.5 Hz); IH, d, 7.74 ppm (J =.8.5 Hz); IH, d, 8.2 ppm (J = 8.51Hz); HRMS: Calculated - 212.0950; Found - 212.0941; TLC: (90:10:1-methylene chloride: methanol:28% aqueous i5 ammonia) R -0.41.

Example 37 8-fluoro-9-amino-l,2,3,4-tetrahydroacridine

To a stirred solution of cyclohexanone (1.0 g, 10.0 mmole) in methylene chloride (10 ml) at -20°C, a

20 IM solution of titanium (IV) chloride in methylene chloride (20 ml) was added. The reaction mixture became yellow in color and to it a mixture of triethylamine (2.0 g,20 mmole) and 2-amino-6-fluoro- benzonitrile (1.36 g,10.0 mmole) in methylene chloride

25 (30 ml) were added. The reaction mixture immediately became dark in color and was allowed to warm to room temperature (about 25°C) and stirred further for 15 hours. At the end of this period, the reaction mixture was treated with 12% aqueous NaOH (100 ml) , and methy-

30 lene chloride (100 ml) . The reaction mixture was then filtered through a 2 inch diatomaceous earth pad (Celite (trademark) ) which was washed with methylene chloride (50 ml) and water (100 ml) . The organic layer was separated, washed with water(1x30 ml) and

35 dried (anhydrous MgSO.). The methylene chloride was

removed under vacuum to afford an oil which was tritu¬ rated with ether to give the title compound as a white solid (218 mg, 10%, m.p. 175°C) . 1 H-NMR (CDC1 3 , 300MHz,/): 4H, m, 2.0 ppm; 2H, t, 2.59 ppm (J = 7.0 5 Hz); 2H, t, 3.06 ppm (J = 7.0 Hz); 2H, bs, 5.37 ppm;

IH, dd, 7.0 ppm (J = 7.5, 14 Hz); IH, dd, 7.46 ppm (J = 8, 16 Hz); IH d, 7.72 ppm (J = 8.5 Hz). HRMS: Calcula¬ ted - 216.1053; Found - 216.1039.

Example 38 - Q 9-Amino-8-methyl-1,2,3,4-tetrahydroacridine

Following the method of Example 37, but substituting 2-amino-6-methylbenzonitrile for 2-amino-6-fluorobenzonitrile, afforded the title compound (11%, m.p. 143-145°C) . 1 H-NMR (CDC1 3 , 300 15 MHZ, £) : IH, d, 7.68 ppm (J = 8 Hz); IH, t, 7.34 ppm (J = 8 Hz); IH, d, 7.02 ppm (J = 8 Hz); 2H, bs, 4.89 ppm; 2H, t, 2.95 (J = 6 Hz); 3H, s, 2.92 ppm; 2H, t, 2.49 ppm (J = 6 Hz); 4H, m, 1.8-2.0 ppm; HRMS: Calculated - 212.1313; Found - 212.1273; TLC: (90:10:l-methylene 2G chloride:methanol:28% aqueous ammonia) Rj.-0.23.

Example 39 9-Amino-8-chloro-l,2,3,4-tetrahydroacridine Following the method of Example 37, but substituting 2-amino-6-chlorobenzonitrile for 2 5 2-amino-6-fluorobenzonitrile, afforded the title compound (23%, m.p. 144-145°C) . X H-NMR (CDC1 3 , 300 MHz,<f) : IH, d, 7.75 ppm (J = 8 Hz); 1 H, t, 7.35 ppm (J=8 Hz); IH, d, 7.27 ppm (J = 8 Hz); 2H, bs, 5.81 ppm; 2H, t, 2.96 ppm (J = 6 Hz); 2H, t, 2.49 ppm (J = 6 Hz); 30 4H, m, 1.96 - 1.86 ppm; HRMS: Calculated - 232.0770; Found - 232.0777; TLC: (90:10:1-methylene chloride: methanol:28% aqueous ammonia) R^-0.62.

Example 40 4-Amino-5-fluoro-2,3-pentamethylenequinoline 35 Following the method of Example 37, but

substituting cvcloheptanone for cyclohexanone, afforded the title compound (22%, m.p. 203°C) . H-NMR (CDC1-, 300 MHz,J) : IH, d, 7.67 ppm (J = 8 Hz) ; IH, dd, 7.39 ppm (J = 8 Hz) ; IH, dd, 6.96 ppm (J = 7, 14 Hz) ; 2H, bs, 5.34 ppm; 2H, m, 3.09 ppm; 2H, m, 2.7 ppm; 6H, m, 1.6-2.0 ppm; HRMS: Calculated - 230.1219; Found - 230.1235; TLC: (ethyl acetate) R f -0.31.

Example 41 4-Amino-5-chloro-2,3-pentamethylenequinoline Following the method of Example 37, but substituting cycloheptanone for cyclohexanone and 2-amino-6-chlorobenzonitrile for 2-Amino-6-fluoro¬ benzonitrile, afforded the title compound (11%, m.p. 194-195°C) . -" " H-NMR (CDC1 3 , 300 MHz,f) : IH, d, 7.79 ppm (J = 7 Hz) ; 2H, m, 7.30-7.39 ppm; 2H, bs, 5.85 ppm; 2H, m, 3.08 ppm; 2H, m, 2.69 ppm; 6H, m, 1.65-2.0 ppm; HRMS: Calculated - 246.0924; Found - 246.0914; TLC: (ethyl acetate) R f -0.34.

Example 42 4-Amino-5-fluoro-2,3-trimethylenequinoline Following the method of Example 37, but substituting cyclopentanone for cyclohexanone, afforded the title compound (6%, m.p. 179-181°C) . H-NMR (CDC1 3 , 300 MHz,?) : IE, d, 7.65 ppm (J = 8 Hz) ; IH, dd, 7.4 Hz (J = 8 Hz) ; IH, dd, 6.93 ppm (J = 7.14 Hz) ; IH, bs, 5.10 ppm; 2H, t, 3.07 ppm (J = 8 Hz) ; 2H, t, 2.8 ppm (J = 8 Hz) ; 2H, quin, 2.1-2.23 ppm (J = 8 Hz) ; HRMS: Calculated - 202.0906; Found - 202.0909; TLC: (90: 10: 1-methylene chloride:methanol: 28% aqueous ammonia) R^-0.52.

Example 43 9-Amino-8-chloro-4-oxo-l ,2,3,4-tetrahydroacridine Following the method of Example 7, but substituting 2-amino-6-chlorobenzonitrile for anthranilonitrile, afforded 'the title compound (15%,

m.p. 205°C) . -" " H-NMR (CDCl j , 300 MHz,J): IH, d, 7.62 ppm (J = 7 Hz); IH, t, 7.31 ppm (J = 7 Hz); IH, d, 7.19 ppm (J = 7 Hz); 2H, bs, 5.81 ppm; 2H, t, 4.31 ppm (J = 6 Hz); 2H, t, 2.52 ppm (J = 6 Hz); 2H, m, 2.11 ppm; HRMS: Calculated - 234.0560; Found - 234.0565; TLC: (ethyl acetate) R f -0.27.

Example 44 9-Amino-8-methyl-4-oxa-l,2,3,4-tetrahydroacridine Following the method of Example 7, but substituting 2-amino—6-methylbenzonitrile for anthranilonitrile, afforded the title compound (20%, m.p. 177-179°C) . -""H-NMR (CDC1 3 , 300 MHz, f) : IH, d, 7.56 ppm (J = 7 Hz); IH, t, 7.31 ppm (J = 7 Hz); IH, d, 6.95 ppm (J = 7 Hz); 2H, bs, 4.93 ppm; 2H, t, 4.29 ppm (J = 6 Hz); 3H, s, 2.89 ppm; 2H, t, 2.52 ppm (J = 6 Hz); 2H, m, 2.08-2.11 ppm; HRMS: Calculated - 214.1106; Found - 214.1097; TLC: (ethyl acetate)

R f -0.27.

Example 45 9-Amino-8-methoxy-l,2,3,4-tetrahydroacridine

Following the method of Example 37, but substituting 2-amino—6-methoxybenzonitrile for 2-amino-6-fluorobenzonitrile, afforded the title compound (14%, m.p. 187-188°C) . "H-NMR (CDC1 3 , 300 MHz,[): IH, d, 7.45 ppm (J = 8.0 Hz); IH, t, 7.37 ppm (J = 8 Hz); IH, d, 6.64 ppm (J = 8 Hz); 2H, bs, 5.88 ppm; 3H, s, 3.96 ppm; 2H, t, 2.95 ppm (J = 7 Hz) ; 2H, t, 2.46 ppm (J = 7 Hz); 4H, , 1.94-1.85 ppm; HRMS: Calculated - 228.1233; Found - 228.1277; TLC: (90:10:l-methylene chloride:mεthanol:28% aqueous ammonia) R f -0.20.

Example 46

9-Amino-8-methoxy-4-oxa-l,2,3,4-tetrahydroacridine Following the method of Example 7, but substituting 2-amino-6-methyoxybenzonitrile for

anthranilonitrile afforded the title compound (11%, m.p. 205-207°C) . -""H-NMR (CDC1 3 , 300 MHz,<f) : 2H, m, 7.33 ppm; IH, dd, 6.57 ppm (J = 3, 6 Hz); 2H, bs, 5.92 ppm; 2H, t, 4.29 ppm (J = 2, 6 Hz); 3H, s, 3.95 ppm; 2H, t, 2.5 ppm (J = 2, 6 Hz); 2H, m, 2.13-2.07 ppm;

TLC: (90:10:l-methylene chloride:methanol:28% aqueous ammonia) R^-0.49.

Example 47 The ability of the title compounds of Examples 1-16, 18, 26-29, and 35-46 to inhibit brain acetyl¬ cholinesterase was determined by the spectrophotometric method of G. L. Ellman et al. (Biochemical Pharmacology, 1_, 88 (1961)). All of the compounds had IC 5Q (molar) values between 5 μM and 0.1 «M.